Author:
Singer Jack W.,Baker Brian,de Vries Peter,Kumar Anil,Shaffer Scott,Vawter Ed,Bolton Mary,Garzone Pamela
Reference32 articles.
1. Maeda, H. 2001. The enhanced permeability and retention (EPR) effect in tumour vasculature: the key role of tumour-selective macromolecular drug targeting. Adv.Enzyme Regul. 41:189–207.
2. Maeda, H., J. Wu, T. Sawa, Y. Matsumura, and K. Hori. 2000. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J.Control. Release 65:271–284.
3. Matsumura, Y. and H. Maeda. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392.
4. Pimm, M. V., A. C. Perkins, J. Strohalm, K. Ulbrich, and R. Duncan. 1996. Gamma scintigraphy of the biodistribution of 123I-labelled n-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J Drug Targeting 3:375–383.
5. Vasey, P. A., S. B. Kaye, R. Morrison, C. Twelves, P. Wilson, R. Duncan, A. H. Thomson, L. S. Murray, T. E. Hilditch, T. Murray, S. Burtles, D. Fraier, E. Frigerio, and J. Cassidy. 1999. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 5:83–94.
Cited by
117 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献